CXCR3 expression on peripheral CD4+ T cells as a predictive marker of response to treatment in chronic hepatitis C

Clinical Immunology

Volumn 132, Issue 1, 2009, Pages 55-62

  Perney, Pascal ^a   Turriere, Chrystell ^b   Portalès, Pierre ^b   Rigole, Hélène ^b   Psomas, Christina ^b   Blanc, François ^b   Clot, Jacques ^b   Corbeau, Pierre ^a,b  

^a DEPARTMENT OF NEUROLOGY   (France)

^b HÔPITAL SAINT ELOI   (France)

Author keywords

Aspartate aminotransferase; CCR5; Chemokine receptor; HCV; HCV load; Interferon; Liver fibrosis; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; MARKER; MEMBRANE ANTIGEN; PEGINTERFERON; RIBAVIRIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN EXPRESSION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4+ T LYMPHOCYTE; CELL DENSITY; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LIVER FIBROSIS; MALE; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT DURATION; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; DRUG THERAPY, COMBINATION; FEMALE; FIBROSIS; FLOW CYTOMETRY; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, CCR5; RECEPTORS, CXCR3; RIBAVIRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67349259571     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.03.521     Document Type: Article

References (41)

1. Pawlotsky J.M. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol. 12 (2004) 96-102
2. Bertoletti A., and Ferrari C. Kinetics of the immune response during HBV and HCV infection. Hepatology 38 (2003) 4-13
3. Napoli J., Bishop G.A., McGuinness P.H., Painter D.M., and McCaughan G.W. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 24 (1996) 759-765
4. Mackay C.R. Chemokines: immunology's high impact factors. Nat. Immunol. 2 (2001) 95-101
5. Bonecchi R., Bianchi G., Bordignon P.P., D'Ambrosio D., Lang R., Borsatti A., Sozzani S., Allavena P., Gray P.A., Mantovani A., and Sinigaglia F. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 helper cells (Th1s) and Th2s. J. Exp. Med. 187 (1998) 129-134
6. Apolinario A., Majano P.L., Alvarez-Perez E., Saez A., Lozano C., Vargas J., and Garcia-Monzon C. Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease. Am. J. Gastroenterol. 97 (2002) 2861-2870
7. Shields P.L., Morland C.M., Salmon M., Qin S., Hubscher S.G., and Adams D.H. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J. Immunol. 163 (1996) 6236-6243
8. Helbig K.J., Ruszkiewicz A., Semendric L., Harley H.A., McColl S.R., and Beard M.R. Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation. Hepatology 39 (2004) 1220-1229
9. Boisvert J., Kunkel E.J., Campbell J.J., Keefe E.B., Butcher E.C., and Greenberg H.B. Liver-infiltrating lymphocytes in end stage hepatitis C virus: subsets, activation status, and chemokine receptor phenotypes. J. Hepatol. 38 (2003) 67-75
10. Harvey C.E., Post J.J., Palladinetti P., Freeman A.J., Ffrench R.A., Kumar R.K., Marinos G., and Lloyd A.R. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J. Leukoc. Biol. 74 (2003) 360-369
11. Cruise M.W., Lukens J.R., Nguyen A.P., Lassen M.G., Waggoner S.N., and Hahn Y.S. Fas ligand is responsible for CXCR3 chemokine induction in CD4+ T cell-dependent liver damage. J. Immunol. 176 (2006) 6235-6244
12. Lichterfeld M., Leifeld L., Nischalke H.D., Rockstroh J.K., Hess L., Sauerbruch T., and Spengler U. Reduced CC chemokine receptor (CCR) 1 and CCR5 surface expression on peripheral blood T lymphocytes from patients with chronic hepatitis C infection. J. Infect. Dis. 185 (2002) 1803-1807
13. Amaraa R., Mareckova H., Urbanek P., and Fucikova T. T helper, cytotoxic T lymphocyte, NK cell and NK-T cell subpopulations in patients with chronic hepatitis C. Folia Microbiol. 47 (2002) 717-722
14. Butera D., Marukian S., Iwamaye A.E., Hembrador E., Chambers T.J., Di Bisceglie A.M., Charles E.D., Talal A.H., Jacobson M., Rice C.M., and Dustin L.B. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood 106 (2005) 1175-1182
15. Desmetz C., Lin Y.-L., Mettling C., Portalès P., Rabesandratana H., Clot J., and Corbeau P. The strength of the chemotactic response to a CCR5 binding chemokine is determined by the level of cell surface CCR5 density. Immunology 119 (2006) 551-561
16. Larrubia J.R., Calvino M., Benito S., Sanz-de-Villalobos E., Perna C., Pérez-Hornedo J., Gonzalez-Mateos F., Garcia-Garzon S., Bienvenido A., and Parra T. The role of CCR5/CXCR3 expressing CD8+ cells in liver damage and viral control during persistent hepatitis C virus infection. J. Hepatol. 47 (2007) 632-641
17. Reynes J., Portales P., Segondy M., Baillat V., André P., Réant B., Avinens O., Couderc G., Benkirane M., Clot J., Eliaou J.-F., and Corbeau P. CD4+ T cell surface CCR5 density as a determining factor of viral load in HIV-1-infected individuals. J. Infect. Dis. 181 (2000) 927-932
18. Blanco J., Cabrera C., Jou A., Ruiz L., Clotet B., and Esté J.A. Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy. AIDS 13 (1999) 547-555
19. Patterson B.K., Czerniewski M., Andersson J., Sullivan Y., Su F., Jiyamapa D., Burki Z., and Landay A. Regulation of CCR5 and CXCR4 expression by type 1 and 2 cytokines: CCR5 expression is downregulated by IL-10 in CD4-positive lymphocytes. Clin. Immunol. 91 (1999) 254-262
20. Loetscher M., Loetscher P., Brass N., Meese E., and Moser B. Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene organization. Eur. J. Immunol. 28 (1998) 3696-3705
21. Reckamp K.L., Figlin R.A., Moldawer N., Pantuck A.J., Belldegrun A.S., Burdick M.D., and Strieter R.M. Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal carcinoma in response to systemic IL-2 therapy. J. Immunother. 30 (2007) 417-424
22. Bermejo M., Martin-Serrano J., Oberlin E., Pedraza M.A., Santiago B., Caruz A., Loetscher P., Baggiolini M., Arenzana-Seisdedos F., and Alcami J. Activation of blood T lymphocytes down-regulates CXCR4 expression and interferes with propagation of X4 strains. Eur. J. Immunol. 28 (1998) 3192-3204
23. Kawakami Y., Nabeshima S., Furusyo N., Sawayama Y., Hayashi J., and Kashiwagi S. Increased frequency of interferon-gamma-producing peripheral blood CD4+ T cells in chronic hepatitis C virus infection. Am. J. Gastroenterol. 95 (2000) 227-232
24. Lin Y.-L., Mettling C., Portalès P., Rouzier R., Clot J., Reynes J., and Corbeau P. The chemokine CCL5 regulates the in vivo cell surface expression of its receptor, CCR5. AIDS 22 (2008) 430-433
25. Apolinario A., Majano P.L., Lorente R., Nunez O., Clemente G., and Garcia-Monzon C. Gene expression profile of T-cell-specific chemokines in human hepatocyte-derived cells: evidence for a synergistic inducer effect of cytokines and hepatitisC virus proteins. J. Viral Hepat. 12 (2005) 27-37
26. Nattermann J., Nischalke H.D., Feldmann G., Ahlenstiel G., Sauerbruch T., and Spengler U. Binding of HCV E2 to CD81 induces RANTES secretion and internalization of CC chemokine receptor 5. J. Viral Hepatitis 11 (2004) 519-526
27. Soo H.M., Garzino-Demo A., Hong W., Tan Y.H., Tan J.T., Goh P.-Y., Lim S.G., and Lim S.P. Expression of a full-length hepatitis C virus cDNA up-regulates the expression of CC chemokines MCP-1 and RANTES. Virology 303 (2002) 253-277
28. Hellier S., Frodsham A.J., Hennig B.J.W., Klenerman P., Knapp S., Ramaley P., Satsangi J., Wright M., Zhang L., Thomas H.C., Thursz M., and Hill A.V.S. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 38 (2003) 1468-1476
29. Nguyen G.T., Carrington M., Beeler J.A., Dean M., Aledort L.M., Blatt P.M., Cohen A.R., Di Michele D., Eyster M.E., Kessler C.M., Konkle B., Leissinger C., Luban N., O'Brien S.J., Goedert J.J., and O'Brien T.R. Phenotypic expressions of CCR5-D32/D32 homozygosity. J. Acquir. Immune Defic. Syndr. 22 (1999) 75-82
30. Woitas R.P., Ahlenstiel G., Iwan A., Rockstroh J.K., Brackmann H.H., Kupfer B., Matz B., Offergeld R., Sauerbruch T., and Spengler U. Frequency of the HIV-protective CC chemokine receptor 5-D32/D32 genotype is increased in hepatitis C. Gastroenterology 122 (2002) 1721-1728
31. Klein R.S. Discussion on frequency of the HIV-protective CC chemokine receptor 5-D32/D32 genotype is increased in hepatitis C. Gastroenterology 124 (2003) 1558
32. Mangia A., Santoro R., D'agruma L., and Anriulli A. HCV chronic infection and CCR5-Δ 32/Δ32. Gastroenterology 124 (2003) 868-869
33. Poljak M., Seme K., Marin I.J., and Babic D.Z. Frequency of the 32-base pair deletion in the chemokine receptor CCR5 gene is not increased in hepatitis C patients. Gastroenterology 124 (2003) 1560-1568
34. Promrat K., McDermott D.H., Gonzalez C.M., Kleiner D.E., Koziol D.E., Lessie M., Merrell M., Soza A., Heller T., Ghany M., Park Y., Alter H.J., Hoofnagle J.H., Murphy P.M., and Liang T.J. Association of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology 124 (2003) 352-3260
35. Zhang J.J., Goedert M., and O'Brien T.R. High frequency of CCR5-D32 homozygosity in HCV-infected, HIV-uninfected hemophiliacs results from resistance to HIV-1. Gastroenterology 124 (2003) 867-868
36. Okuda M., Li K., Beard M.R., Showalter L.A., Scholle F., Lemon S.M., and Weinman S.A. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122 (2002) 366-375
37. Giannini E., Risso D., Botta F., Chiarbonello B., Fasoli A., Malfatti F., Romagnoli P., Testa E., Ceppa P., and Testa R. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ration in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch. Int. Med. 163 (2003) 218-224
38. Wai C.T., Greenson J.K., Fontana R.J., Kalbfleisch J.D., Marrero J.A., Conjeevaram H.S., and Lok A.S. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronis hepatitis C. Hepatology 38 (2003) 518-526
39. Poynard T., Yuen M.F., Ratziu V., and Lai C.L. Viral hepatitis C. Lancet 362 (2003) 2095-2100
40. Helbig K.J., George J., and Beard M.R. A novel I-TAC promoter polymorphism variant is functional in the presence of replicating HCV in vitro. J. Clin. Virol. 32 (2005) 137-143
41. Chen J., Vistica B.P., Takase H., Ham D.I., Fariss R.N., Wawrousek E.F., Chan C.-C., DeMartino J.A., Farber J.M., and Gery I. A unique pattern of up- and down-regulation of chemokine receptor CXCR3 on inflammation-inducing Th1 cells. Eur. J. Immunol. 34 (2004) 2885-2894